Skip to main content

Day: October 3, 2021

Notice Regarding Nidec Corporation’s Board Resolution on Selection for TSE’s New “Prime Market” Segment

Written by Customer Service on . Posted in Public Companies.

KYOTO, Japan, Oct. 04, 2021 (GLOBE NEWSWIRE) — On July 9, 2021, Nidec Corporation (the “Company”) received an initial assessment result from the Tokyo Stock Exchange (TSE) regarding the listing criteria for the bourse’s new market segments, which confirmed that the Company fulfilled the requirements for listing on the bourse’s main Prime Market board. Based on these results, the Company’s board of directors resolved at its meeting held on October 3, 2021 to select to list on the Prime Market as the TSE transitions to three new market segments with tighter listing criteria, and to submit the relevant applications. Going forward, the Company will adhere to the prescribed procedures stipulated in the TSE application schedule. Contact:Masahiro NagayasuGeneral ManagerInvestor Relations+81-75-935-6140ir@nidec.com

Continue reading

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

Written by Customer Service on . Posted in Public Companies.

BURNABY, British Columbia, Oct. 03, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time.A conference call and webcast with slides will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4481713.The above listed dates and times are subject to change. When available, webcasts will be posted for replay following the event. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing...

Continue reading

Active Biotech: Tasquinimod clinical  development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Written by Customer Service on . Posted in Public Companies.

Lund Sweden, October 3, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the ongoing trial of tasquinimod in multiple myeloma has reached an important milestone. Ten patients have been treated with increasing doses of tasquinimod, which was generally well tolerated. The optimal dose and schedule of tasquinimod, when used as a single agent in patients with multiple myeloma has been established at 1 mg per day after a one-week run in of 0.5 mg daily. This is similar to the treatment schedule used in previous studies of tasquinimod. The trial will now advance to a previously planned combination part, in which treatment with tasquinimod will be tested in patients with multiple myeloma together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd). Once an optimal dose and...

Continue reading

Festi hf.: Buy-back programme week 39

Written by Customer Service on . Posted in Public Companies.

In week 39 Festi purchased in total 1,249,121 own shares for total amount of 264,106,620 ISK as follows:Week Date Time Purchased shares Share Price Purchase price39 27.9.2021 14:12:41 150.000 208,000 31.200.00039 27.9.2021 15:29:39 100.000 208,000 20.800.00039 28.9.2021 13:10:48 150.000 208,000 31.200.00039 28.9.2021 14:52:29 100.000 208,000 20.800.00039 29.9.2021 10:42:20 100.000 206,000 20.600.00039 29.9.2021 13:25:45 100.000 207,000 20.700.00039 29.9.2021 15:12:09 50.000 210,000 10.500.00039 30.9.2021 12:53:56 1.060 214,000 226.84039 30.9.2021 12:59:30 1 214,000 21439 30.9.2021 13:08:33 98.939 214,000 21.172.94639 30.9.2021 13:09:10 150.000 214,000 32.100.00039 1.10.2021 11:16:48 94.090 220,000 20.699.80039 1.10.2021 12:31:01 1.500 220,000 330.00039 1.10.2021 14:06:37 150.000 220,000 33.000.00039 1.10.2021 14:33:44 3.531 220,000 776.820      1.249.121   264.106.620Before...

Continue reading

Roper Technologies to Sell TransCore for $2.68 Billion

Written by Customer Service on . Posted in Mergers And Acquisitions.

SARASOTA, Fla., Oct. 03, 2021 (GLOBE NEWSWIRE) — Roper Technologies, Inc. (NYSE: ROP), a leading diversified technology company, today announced that it has reached a definitive agreement to divest its TransCore business to Singapore Technologies Engineering Ltd (“ST Engineering”), a global technology, defense, and engineering group, for $2.68 billion in cash. TransCore is expected to generate approximately $545 million of revenue and $135 million of EBITDA in 2021. Roper will retain its DAT and Loadlink network software businesses, which it acquired together with TransCore in 2004. “ST Engineering will be a great owner for TransCore and will support the business as it pursues the next phase of its innovative work in traffic management, tolling technology, and smart city infrastructure,” said Neil Hunn, Roper Technologies’ President...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.